Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar 13 versus Pneumovax immunogenicity in adult kidney and liver transplant patients
2012-002657-30Phase 3Completed
- Sponsor
- HYKS Institute
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by HYKS Institute. Primary endpoint: Immunogenicity difference between PCV13 and PPV23 groups. Started Aug 2012; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2012-002657-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002657-30.